BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2658540)

  • 21. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide and cisplatinum combination chemotherapy for the treatment of epithelial ovarian carcinoma.
    Hahn K; Magrina JF; Masterson BJ
    Int J Gynaecol Obstet; 1985 Dec; 23(6):509-13. PubMed ID: 2868947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of advanced ovarian cancer with cisplatin, adriamycin, and cyclophosphamide: effect of treatment and incidence of intracranial metastases.
    Budd GT; Webster KD; Reimer RR; Martimbeau P; Livingston RB
    J Surg Oncol; 1983 Nov; 24(3):192-5. PubMed ID: 6685214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
    Gershenson DM; Copeland LJ; Kavanagh JJ; Stringer CA; Saul PB; Wharton JT
    Obstet Gynecol; 1987 Nov; 70(5):765-9. PubMed ID: 3658288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
    J Clin Oncol; 1991 Sep; 9(9):1668-74. PubMed ID: 1831495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of the combination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma.
    Russo A; Gebbia V; Palmeri S; Geraci P; Maneschi F; Guarnieri G; Carollo F; Leonardi V; Meli M; Gebbia N
    Eur J Gynaecol Oncol; 1993; 14(3):228-33. PubMed ID: 8508880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
    Greco FA; Johnson DH; Hainsworth JD
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of fallopian tube carcinoma with cyclophosphamide, adriamycin, and cisplatin.
    Cormio G; Maneo A; Gabriele A; Zanetta G; Losa G; Lissoni A
    Am J Clin Oncol; 1997 Apr; 20(2):143-5. PubMed ID: 9124187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.
    Wils J; van Geuns H; Stoot J; Bergmans M; Boschma F; Bron H; Degen J; Erdkamp F; van Erp J; Haest J; Iding R; Lalisang F; de Pree N; de Rooy C; Snijders M; Schepers J; Vreeswijk J; Wals J; Werter M; Wetzels L; Smeets J; Schouten L
    Anticancer Drugs; 1999 Mar; 10(3):257-61. PubMed ID: 10327029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of second-look laparotomy in the management of patients with stage II, III and IV ovarian cancers following chemotherapy with cisplatin, adriamycin and cyclophosphamide.
    Kirwan PH; Naftalin NJ; Khanna S; Aukett RJ
    Br J Obstet Gynaecol; 1986 Jun; 93(6):629-33. PubMed ID: 3730331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.
    Omura GA; Brady MF; Homesley HD; Yordan E; Major FJ; Buchsbaum HJ; Park RC
    J Clin Oncol; 1991 Jul; 9(7):1138-50. PubMed ID: 1904477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. The Gynecologic Oncology Group of the Comprehensive Cancer Center, Limburg, The Netherlands.
    Stoot J; Wils J; von Geuns H; Smeets J; Schouten L
    Cancer Invest; 1993; 11(1):1-5. PubMed ID: 8422593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abdominopelvic irradiation for stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy.
    Menczer J; Modan M; Brenner J; Ben-Baruch G; Brenner H
    Gynecol Oncol; 1986 Jun; 24(2):149-54. PubMed ID: 3710262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
    Hunter RE; Griffin TW; Stevens S; Roman LD; Bokhari F; Reale FR; Tak WK; Fitzgerald TJ; Dillon MB; Rose PG
    Cancer; 1991 Nov; 68(9):1890-4. PubMed ID: 1655227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
    Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
    Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).
    Gadducci A; Brunetti I; Bruzzone M; Carnino F; Chiara S; Conte PF; Fioretti P; Foglia G; Ragni N
    Eur J Gynaecol Oncol; 1992; 13(1 Suppl):36-9. PubMed ID: 1511712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.